Pros | Among most bought funds within the category. Beats FD returns for both 3Y & 5Y duration. | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 4/8 | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 7 Years | ||
Fund Size | 3074 Cr | 6227 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.6% | 1.03% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 32 | 43 | ||
Top 5 Holdings | Cipla Ltd (8.76%) Sun Pharmaceuticals Industries Ltd (7.96%) Cohance Lifesciences Ltd (7.9%) Ipca Laboratories Ltd (7.39%) Laurus Labs Ltd (6.07%) | Sun Pharmaceuticals Industries Ltd (11.58%) Dr Reddy's Laboratories Ltd (9.1%) Divi's Laboratories Ltd (8.75%) Aurobindo Pharma Ltd (8.25%) Cipla Ltd (6.92%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (98.48%) Financial Services (1.52%) | Health (97.7%) Basic Materials (1.18%) Financial Services (1.12%) | ||
Equity % | 97.95% | 97.55% | ||
Debt % | - | - | ||
P/E | 33.91 | 30.65 | ||
P/B | 5.05 | 4.17 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.8% | 0.54% | ||
3-Month Return | 2.84% | 1.41% | ||
6-Month Return | 8.64% | 8.2% | ||
1-Year Return | -2.8% | 3.78% | ||
3-Year Return | 23.05% | 27.3% | ||
5-Year Return | 19.17% | 21.18% |
Sharpe | 1.07 | 1.26 | ||
Alpha | 2.02 | 4.3 | ||
Beta | 0.84 | 0.95 | ||
Standard Deviation | 14.65 | 15.69 | ||
Information Ratio | -0.08 | 1.4 |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Dharmesh Kakkad,Sharmila D’mello |